Medrad chief executive Witmer to retire

Article

Medrad announced this month that its president and CEO Thomas Witmer is planning to retire. Witmer has led the Indianola, PA, manufacturer of contrast injection systems for the last 16 years, and saw the company through its acquisition by German contrast

Medrad announced this month that its president and CEO Thomas Witmer is planning to retire. Witmer has led the Indianola, PA, manufacturer of contrast injection systems for the last 16 years, and saw the company through its acquisition by German contrast agent developer Schering in 1995 (SCAN 8/30/95). Medrad senior vice president and general manager John Friel has been tapped to replace Witmer as president and CEO in a transition process to be phased in over the next several months. Witmer will remain on Medrad's board.

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.